Phaseline

Companies › Aramis Biotechnologies

Aramis Biotechnologies: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Infectious disease; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Plant-Based Seasonal Recombinant Trivalent TVLP Influenza Vaccine
Recombinant trivalent virus-like particles (VLPs) expressing influenza antigens produced i
–Phase 1InfluenzaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07291635Plant-Based Seasonal Recombinant Trivalent TVLP Influenza VaccinePhase 1InfluenzaInfectious diseaseDec 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.